Transforming Preeclampsia Care: Molecular Diagnostics and Therapeutic Innovations

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Nephrology

Background:

• Preeclampsia is a major global cause of maternal and perinatal mortality.
• Circulating anti-angiogenic factors, including soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin, are key to preeclampsia pathogenesis.
• Understanding these factors has revolutionized the study of preeclampsia.

Purpose of the Study:

• To review recent advancements in understanding preeclampsia pathogenesis.
• To highlight the development and clinical integration of molecular diagnostics.
• To discuss emerging therapeutic strategies and long-term health implications.

Main Methods:

• Review of recent scientific discoveries and clinical practice.
• Analysis of molecular diagnostics (sFlt-1, placental growth factor (PlGF), and their ratio).
• Exploration of emerging therapeutic approaches and long-term risks.

Main Results:

• The identification of sFlt-1 and soluble endoglin has transformed preeclampsia understanding.
• Molecular diagnostics like the sFlt-1/PlGF ratio are now clinically integrated for prediction and diagnosis.
• Emerging therapies show promise for disease modification, and long-term risks are recognized.

Conclusions:

• Preeclampsia management has advanced significantly due to insights into anti-angiogenic factors.
• Continued innovation and clinical trial inclusion are crucial for developing safe and effective future treatments.
• Preeclampsia has lifelong cardiovascular and kidney implications for mothers and pulmonary risks for offspring.